New article on pioglitazone use and risk of mortality in patients with type 2 diabetes

30.5.2017 – Our new article on pioglitazone use and risk of mortality in patients with type 2 diabetes has been published in BMJ Open.

Life expectancy is 5–10 years shorter in adult patients with newly-diagnosed diabetes than in the general population. Cardiovascular diseases are the leading cause of death in this patient group. Pioglitazone, which is an oral antidiabetic agent, has been shown to carry beneficial effects in patients with type 2 diabetes.

The present study included 56 337 patients with type 2 diabetes first prescribed pioglitazone between years 2000 and 2011, and 56 337 matched control patients never prescribed pioglitazone. Clinical data was collected from primary and/or secondary care in Finland, the Netherlands, Sweden and the UK.

We analysed this large pan-European cohort and found a statistically significant 33% reduction in the risk of all-cause mortality when comparing pioglitazone to alternative antidiabetic medication at the same stage of disease progression. Number of cases of bladder cancer-specific mortality was small hindering the possibilities to make conclusions about this cause-specific mortality in relation to pioglitazone use.

Strongman H, Korhonen P, Williams R, et al Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. Published in BMJ Open Diabetes Research and Care 2017;5:e000364. doi: 10.1136/bmjdrc-2016-000364. – Read full article